Toward a Safe and Efficacious Pan-Leishmania Vaccine-Reference-Cited by-同舟云学术

Toward a Safe and Efficacious Pan-Leishmania Vaccine

Published:2023 Issue: Volume: Page:325-340
ISSN:
Container-title:Challenges and Solutions Against Visceral Leishmaniasis
language:en
Short-container-title:

Author:

Bhattacharya Parna,Volpedo Greta,Pacheco-Fernandez Thalia,Dey Ranadhir,Matlashewski Greg,Satoskar Abhay R.,Singh Sanjay,Gannavaram Sreenivas,Nakhasi Hira L.

Publisher

Springer Nature Singapore

Link

https://link.springer.com/content/pdf/10.1007/978-981-99-6999-9_13

Reference84 articles.

1. Adaui V et al (2020) Application of CRISPR/Cas9-based reverse genetics in leishmania braziliensis: conserved roles for HSP100 and HSP23. Genes (Basel) 11. https://doi.org/10.3390/genes11101159

2. Andrade-Narvaez FJ, Loría-Cervera EN, Sosa-Bibiano EI, Van Wynsberghe NR (2016) Asymptomatic infection with American cutaneous leishmaniasis: epidemiological and immunological studies. Mem Inst Oswaldo Cruz 111:599–604. https://doi.org/10.1590/0074-02760160138

3. Avishek K et al (2016) Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. Sci Rep 6:33059. https://doi.org/10.1038/srep33059

4. Baker N et al (2021) Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival. Nat Commun 12:1244. https://doi.org/10.1038/s41467-021-21360-8

5. Banerjee A et al (2018) Live attenuated leishmania donovani centrin gene-deleted parasites induce IL-23-dependent IL-17-protective immune response against visceral leishmaniasis in a murine model. J Immunol 200:163–176. https://doi.org/10.4049/jimmunol.1700674